• 제목/요약/키워드: anticancer drugs

검색결과 339건 처리시간 0.036초

Combinatorial Biosynthesis of Polyketide Antibiotics Doxorubicin and Rubradirin

  • Hong, Young-Soo;Lee, Jung-Joon;Sohng, Jae-Kyung;Yoo, Jin-Chul;Kim, Chun-Gyu
    • 대한약학회:학술대회논문집
    • /
    • 대한약학회 2003년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.2-1
    • /
    • pp.79-80
    • /
    • 2003
  • A lot of polyketide antibiotics have been isolated from natural sources like microorganism, fungi and plant. The polyketide natural products have biologically and medically important activities, including antibacterial, anticancer, antiparasitic, and immunosuppressant properties. The diversified activities of polyketides are originated from their structural variety of which have been took advantage by several research groups for development of new drugs. (omitted)

  • PDF

Synthesis of 1,2,3-and 1,2,4-Triazole Isonucleosides as Potential antiviral agents

  • Jeong, Soon-Yong;Kim, Myong-Jung;Chun, Moon-Won
    • 대한약학회:학술대회논문집
    • /
    • 대한약학회 2003년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.2-2
    • /
    • pp.181.2-181.2
    • /
    • 2003
  • Inosine monophosphate dehydrogenase(IMPDH) catalyzes the $NAD^+$-dependent oxidation of IMP to XMP, the rate limiting step in the de novo biosynthesis of guanine nucleotide. Its critical role at the metabolic branch point in purine nucleotide biosynthesis makes it a useful target in the development of drugs for antiviral and anticancer chemotherapy and in immunosupressant area. Several compound with antiviral activity have been found to be inhibitors of IMPDH. For example, ribavirin, a competitive inhibitor of IMPDH, has broad spectrum antiviral activities against DNA and RNA viruses. (omitted)

  • PDF

Virtual Screening, Docking and DFT Study of PRMT5

  • Subathra, S
    • 통합자연과학논문집
    • /
    • 제15권4호
    • /
    • pp.187-194
    • /
    • 2022
  • Protein Arginine Methyltransferase 5 (PRMT5), a significant member of the PRMT family, is a promising anticancer target. In this study, novel small compounds that act against the PRMT5 target are found by combining virtual screening with ChEMBL database medicines and Density Functional Theory. The ChEMBL database compounds were screened to retrieve the hit molecules, which further subjected for DFT analysis. Finally we have evaluated that ChEMBL- approved drugs such as Lifitegrast, Abiraterone acetate and Solifenacin may be potential inhibitors for PRMT5.

항암제 내성 위암 세포주 SNU-1의 내성생성기전에 관한 연구 (Study for Metabolism of Resistant Production in Anticancer drug Resistant Stomach Cancer Cell SNU-1)

  • 김정희;강미화;김재룡
    • Journal of Yeungnam Medical Science
    • /
    • 제6권2호
    • /
    • pp.195-205
    • /
    • 1989
  • 암의 화학요법에 있어서 내성생성으로 인한 치료의 장애가 암 치료 실패의 중요 원인이 되며, 분 연구는 암세포의 항암제에 대한 내성 생성에 대한 특성을 연구 보고하였다. 사람의 위암 세포주 SNU-1에 대한 내성 유발을 위하여 세포배양액에 adriamycin(ADR) 농도를 $10^{-8}M$에서 $10^{-7}M$에 까지 적용시켜 내성세포주를 얻어 SUN-1/ADR로 나타내었으며 세포 성장은 SUN-1에서는 2일부터 6일까지 서서히 상승하였고 SNU-1/ADR은 $5{\times}10^3$celles/ml 농도 이상에서 상승을 보였다. 각 세포의 doubling 시간과 doubling 수를 비교하였으며 SNU-1은 doubling 시간이 평균 27.2 시간 doubling 수가 3.56번 이었으며, SNU-1/ADR은 52.2 시간 1.85번으로 내성세포가 더욱 성장이 왕성한 것을 관찰할 수 있다. MTT assay를 위하여 4일간의 성장으로 세포의 적절한 생존도를 관찰하였다. SNU-1과 내성세포주 SNU-1/ADR을 각각 항암제에 대한 약제 감수성 검사를 실시하였으며 약제농도 50%에서 생존도($IC_{50}$)를 비교하여 상관내성도(relative resistance : RR)을 측정 하였으며 vinblastine이 31.62이상으로 가장 높고, vincristine이 29.5, dactinomycin 21.37, epirubicin 17.78, daunorubicin 14.12였고, adriamycin 7.76이었으며 etoposide 4.46 이었다. 그 외의 약제 5-fluorouracil, cisplatin, cyclophosphamide, methotrexate, aclarubicin은 감수성이 낮았다. 위의 결과로 RR가 높은 약제들에 대해서는 multidrug resistance(복합내성)의 존재를 의미한다고 할 수 있으며 내성생성 SNU-1/ADR 세포주의 염색체의 검사에서 double minute chromosome(DMs)을 확인함으로서 내성 생성 세포를 확인 하였다.

  • PDF

암세포주에 대한 유근피 n-BuOH 분획과 항암제의 병용효과 (The Combined Effects of n-BuOH Fraction of Ulmi Cortex and Anticancer Drugs on Cancer Cell Lines)

  • 은재순;송원영
    • 생약학회지
    • /
    • 제25권2호
    • /
    • pp.144-152
    • /
    • 1994
  • The combined effects of Ulmi Cortex and some anti-cancer drugs on the proliferation of HeLa cells, Hep G2 cells and S 180 cells were estimated by MTT calorimetric assay. The n-BuOH fraction(UBF) of Ulmi Cortex inhibited the proliferation of HeLa cell at $10^{-3}\;g/ml$, Hep G2 cell at $10^{-5}\;g/ml$ and S 180 cell at $10^{-3}\;g/ml$. The inhibitory effects of mitomycin C(MMC), cisplatin(CPT) and 5-fluorouracil (5-FU), respectively, on Hep G2 cell was increased by the UBF. The UBF did not influence the proliferation of Balb/c 3T3 cells at concentrations of $10^{-6}$ to $10^{-4}\;g/ml$, but increased the proliferation of T cells at concentrations of $10^{-5}$ to $10^{-4}\;g/ml$. The UBF did not influence the number of leukocyte, and on the thymus weight of mice. The UBF increased the number of total-peritoreal cells of mice. In conclusion, the results suggest that the UBF have anti-cancer activity without the side effect, such as leukopenia and immunosuppresion, and increase the inhibitory activity of the anti-cancer drugs on Hep G2 cells.

  • PDF

의약분업 전후 일부 종합병원의 약제종류별 약제비 삭감추이 (Trends on the Curtailment of Drug Expenditure Before and After the Seperation between Prescription and Dispensing in General Hospitals By Drug Types)

  • 이선희;조희숙;이혜진;보험심사간호사회
    • 한국병원경영학회지
    • /
    • 제8권2호
    • /
    • pp.93-110
    • /
    • 2003
  • Fiscal crisis in the medical insurance has put the pressure upon hospitals by increasing the rate of curtailment, since the implementation of the separation between prescription and dispensing of Drug. The purpose of this study is to analyze the curtailment for antibiotics, injected drug and other drugs expenditure before and after the system of separation between prescribing and dispensing. Data were gathered from 13 general hospitals and used for analysis of trends on antibiotics and injected drug expenditure, and curtailment in 2000-2001 at three months intervals. The results were as follows; The curtailment rate of antibiotics expenditure has been increased in outpatient and inpatient since 2000. The curtailed antibiotics cost and injected drug cost in outpatient under the prescription within the hospital and in inpatient increased. The ratios of curtailment versus expenditure had increased in antibiotics, injected drugs, anticancer drugs, antiulcer drugs, albumine, antiinflammatory drugs. These results suggest that claim review system in social health insurance were over-focused mainly to control the cost and it might to impede the validity of claim review function in health insurance system. Therefore, it's needed to develope the scientific and reasonable parameter & criteria for claim review of drug expenditure.

  • PDF

Effect of 5-FU and MTX on the Expression of Drug-resistance Related Cancer Stem Cell Markers in Non-small Cell Lung Cancer Cells

  • Yi, Hee;Cho, Hee-Jung;Cho, Soo-Min;Jo, Kyul;Park, Jin-A;Lee, Soo-Han;Chang, Byung-Joon;Kim, Jin-Suk;Shin, Ho-Chul
    • The Korean Journal of Physiology and Pharmacology
    • /
    • 제16권1호
    • /
    • pp.11-16
    • /
    • 2012
  • Cancer stem cells (CSCs) are often characterized by the elevated expression of drug-resistance related stem-cell surface markers, such as CD133 and ABCG2. Recently, we reported that CSCs have a high level of expression of the IL-6 receptor (IL-6R). The purpose of this study was to investigate the effect of anticancer drugs on the expression of the drug resistance-related cancer stem cell markers, ABCG2, IL-6R, and CD133 in non-small cell lung cancer (NSCLC) cell lines. A549, H460, and H23 NSCLC cell lines were treated with the anticancer drugs 5-fluorouracil (5-FU; $25{\mu}g/ml$) and methotrexate (MTX; $50{\mu}g/ml$), and the expression of putative CSC markers was analyzed by fluorescent activated cell sorter (FACS) and the gene expression level of abcg2, il-6r and cd133 by reverse transcriptase-polymerase chain reaction (RT-PCR). We found that the fraction of ABCG2-positive(+) cells was significantly increased by treatment with both 5-FU and MTX in NSCLC cells, and the elevation of abcg2, il-6r and cd133 expressions in response to these drugs was also confirmed using RT-PCR. Also, the number of IL-6R(+) cells was increased by MTX in the 3 cell lines mentioned and increased by 5-FU in the H460 cell line. The number of CD133(+) cells was also significantly increased by both 5-FU and MTX treatment in all of the cell lines tested. These results indicate that 5-FU and MTX considerably enhance the expression of drug-resistance related CSC markers in NSCLC cell lines. Thus, we suggest that antimetabolite cancer drugs, such as 5-FU and MTX, can lead to the propagation of CSCs through altering the expression of CSC markers.

Prescription, Transcription and Administration Errors in Out-Patient Day Care Unit of a Regional Cancer Centre in South India

  • Mathaiyan, Jayanthi;Jain, Tanvi;Dubashi, Biswajit;Batmanabane, Gitanjali
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제17권5호
    • /
    • pp.2611-2617
    • /
    • 2016
  • Background: Medication errors are common but most often preventable events in any health care setup. Studies on medication errors involving chemotherapeutic drugs are limited. Objective: We studied three aspects of medication errors - prescription, transcription and administration errors in 500 cancer patients who received ambulatory cancer chemotherapy at a resource limited setting government hospital attached cancer centre in South India. The frequency of medication errors, their types and the possible reasons for their occurrence were analysed. Design and Methods: Cross-sectional study using direct observation and chart review in anmbulatory day care unit of a Regional Cancer Centre in South India. Prescription charts of 500 patients during a three month time period were studied and errors analysed. Transcription errors were estimated from the nurses records for these 500 patients who were prescribed anticancer medications or premedication to be administered in the day care centre, direct observations were made during drug administration and administration errors analysed. Medical oncologists prescribing anticancer medications and nurses administering medications also participated. Results: A total of 500 patient observations were made and 41.6% medication errors were detected. Among the total observed errors, 114 (54.8%) were prescription errors, 51(24.5%) were transcribing errors and 43 (20.7%) were administration errors. The majority of the prescription errors were due to missing information (45.5%) and administration errors were mainly due to errors in drug reconstitution (55.8%). There were no life threatening events during the observation period since most of the errors were either intercepted before reaching the patient or were trivial. Conclusions: A high rate of potentially harmful medication errors were intercepted at the ambulatory day care unit of our regional cancer centre. Suggestions have been made to reduce errors in the future by adoption of computerised prescriptions and periodic sensitisation of the responsible health personnel.

PLGA-Based Nanoparticles as Cancer Drug Delivery Systems

  • Tabatabaei Mirakabad, Fatemeh Sadat;Nejati-Koshki, Kazem;Akbarzadeh, Abolfazl;Yamchi, Mohammad Rahmati;Milani, Mortaza;Zarghami, Nosratollah;Zeighamian, Vahideh;Rahimzadeh, Amirbahman;Alimohammadi, Somayeh;Hanifehpour, Younes;Joo, Sang Woo
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권2호
    • /
    • pp.517-535
    • /
    • 2014
  • Poly (lactic-co-glycolic acid) (PLGA) is one of the most effective biodegradable polymeric nanoparticles (NPs). It has been approved by the US FDA to use in drug delivery systems due to controlled and sustained-release properties, low toxicity, and biocompatibility with tissue and cells. In the present review, the structure and properties of PLGA copolymers synthesized by ring-opening polymerization of DL-lactide and glicolide were characterized using 1H nuclear magnetic resonance spectroscopy, gel permeation chromatography, Fourier transform infrared spectroscopy and differential scanning calorimetry. Methods of preparation and characterization, various surface modifications, encapsulation of diverse anticancer drugs, active or passive tumor targeting and different release mechanisms of PLGA nanoparticles are discussed. Increasing experience in the application of PLGA nanoparticles has provided a promising future for use of these nanoparticles in cancer treatment, with high efficacy and few side effects.